| Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP … M Bazinet, V Pântea, V Cebotarescu, L Cojuhari, P Jimbei, J Albrecht, ... The lancet Gastroenterology & hepatology 2 (12), 877-889, 2017 | 249 | 2017 |
| Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon alfa-2a in patients with chronic HBV infection naïve to nucleos (t) ide therapy M Bazinet, V Pântea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Gastroenterology 158 (8), 2180-2194, 2020 | 200 | 2020 |
| Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139‐Ca and pegylated interferon therapy in chronic hepatitis B virus/hepatitis delta … M Bazinet, V Pântea, V Cebotarescu, L Cojuhari, P Jimbei, M Anderson, ... Hepatology communications 5 (2), 189-202, 2021 | 72 | 2021 |
| Modelling hepatitis D virus RNA and HBsAg dynamics during nucleic acid polymer monotherapy suggest rapid turnover of HBsAg L Shekhtman, SJ Cotler, L Hershkovich, SL Uprichard, M Bazinet, ... Scientific Reports 10 (1), 7837, 2020 | 36 | 2020 |
| Update on safety and efficacy in the REP 401 protocol: REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated Interferon alpha-2a in … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Journal of Hepatology 66 (1), S256-S257, 2017 | 34 | 2017 |
| Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co … M Bazinet, V Pantea, V Cebotarescu, L Cojuhari, P Jimbei, A Vaillant Journal of Hepatology 68, S509, 2018 | 25 | 2018 |
| Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in Caucasian patients with chronic HBV/HDV co-infection M Bazinet, V Pantea, V Cebotarescu, L Cojuhari, P Jimbei, A Vaillant J Hepatol 62 (Suppl), 2015 | 25 | 2015 |
| Update on the safety and efficacy of REP 2139 monotherapy and subsequent combination therapy with pegylated interferon alpha-2a in Caucasian patients with chronic HBV/HDV co … M Bazinet, V Pantea, V Cebotarescu, L Cojuhari, P Jimbei, J Albrecht, ... Journal of Hepatology 2 (64), S584-S585, 2016 | 20 | 2016 |
| Analysis of HBsAg Immunocomplexes and cccDNA activity during and persisting after NAP‐based therapy M Bazinet, M Anderson, V Pântea, G Placinta, I Moscalu, V Cebotarescu, ... Hepatology Communications 5 (11), 1873-1887, 2021 | 13 | 2021 |
| Establishment of high rates of functional cure of HBeAg negative chronic HBV infection with REP 2139-Mg based combination therapy: ongoing follow-up results from the REP 401 study M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Age (average/median) 36, 36, 2019 | 13 | 2019 |
| Updated follow-up analysis in the REP 401 protocol: Treatment HBeAg negative chronic hepatitis B infection with REP 2139 or REP 2165, tenofovir disoproxil fumarate and … A Vaillant, M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, ... Journal of Hepatology 68, S517, 2018 | 13 | 2018 |
| HBsAg isoform dynamics during NAP‐based therapy of HBeAg‐negative chronic HBV and HBV/HDV infection M Bazinet, M Anderson, V Pântea, G Placinta, I Moscalu, V Cebotarescu, ... Hepatology communications 6 (8), 1870-1880, 2022 | 12 | 2022 |
| Benefit of transaminase elevations in establishing functional cure of HBV infection during NAP‐based combination therapy M Bazinet, V Pântea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Journal of Viral Hepatitis 28 (5), 817-825, 2021 | 11 | 2021 |
| Hepatita virală C acută V Pântea, C Spînu, L Cojuhari, V Cebotărescu Particularităţile clinice, epidemiologice, imunologice și de tratament la …, 2009 | 10 | 2009 |
| One year follow-up and HBV RNA/HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV/HDV co-infection M Bazinet, V Pantea, V Cebotarescu, L Cojuhari, P Jimbei, A Krawczyk, ... J Hepatol 66 (1), S96-7, 2017 | 9 | 2017 |
| Preliminary safety and efficacy of REP 2139-Mg or REP 2165-Mg used in combination with tenofovir disoproxil fumarate and pegylated interferon alpha 2a in treatment naïve … M Bazinet, V Pantea, G Placinta, I Moscalu, V Cebotarescu, L Cojuhari, ... Hepatology 64 (6), 1122A-1123A, 2016 | 9 | 2016 |
| Analysis of HBsAg levels, HBsAg isoforms, HBsAg immune complexes, HBV pregenomic RNA and HBcrAg dynamics during and after NAP-based combination therapy in the REP 301-LTF and … M Bazinet, M Anderson, V Pantea, G Placinta, I Moscalu, V Cebotarescu, ... Journal of Hepatology 73, S142, 2020 | 8 | 2020 |
| Persistent control of HBV and HDV infection following REP 2139-Ca and pegIFN therapy in chronic HBV/HDV co-infection M Bazinet, V Pantea, V Cebotarescu, L Cojuhari, P Jimbei, M Anderson, ... Hepatol Commun 5, 189-292, 2020 | 8 | 2020 |
| REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian patients with chronic HBV/HDV co-infection M Bazinet, V Pantea, V Cebotarescu, L Cojuhari, P Jimbei, A Vaillant J. Viral Hepatitis 22, 5-6, 2015 | 8 | 2015 |
| Treatment of HBV/HDV co-infection with REP-2139 and pegylated interferon M Bazinet, V Pântea, V Cebotarescu, L Cojuhari, P Jimbei, J Albrecht Lancet Gastroenterol Hepatol 2, 877-889, 2017 | 7 | 2017 |
